IP Library Granted Patent US 9,233,090
Granted Patent B2
US 9,233,090 · App. 13/880,923 · Granted Jan 12, 2016

Cysteine and food intake

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,233,090
App. No.
13/880,923
Granted
Jan 12, 2016
Kind
B2
Abstract

The present invention relates to the field of nutrition; in particular to the prevention and/or treatment of malnutrition. One embodiment of the present invention relates to a nutritional composition enriched in cysteine for use in the treatment and/or prevention of malnutrition and disorders related thereto. Such a composition may in particular, but not exclusively, be useful for the elderly population.

Claims (27)

1. A method for the treatment of malnutrition and/or a disorder related thereto in an elderly subject in need thereof, the method comprising administering to the elderly subject a nutritional composition that contains from about 20 to 70% of the calories of the nutritional composition from carbohydrates, and a protein fraction comprising at least 5 weight-% cysteine to increase food intake and/or decrease satiety and/or satiation.

2. The method in accordance with claim 1 , wherein the cysteine is provided in a form of a cysteine precursor selected from the group consisting of cysteine bound in a protein, a peptide hydrolysate, a peptide, and mixed disulfides.

3. The method in accordance with claim 1 , wherein the nutritional composition comprises the cysteine in an amount of at least 2 g/kg dry weight of the composition.

4. The method in accordance with claim 1 , wherein the cysteine increases appetite.

5. The method in accordance with claim 1 , wherein the disorder related to malnutrition is selected from the group consisting of anorexia, anorexia nervosa, cachexia, inflammatory diseases associated with decreased food intake, and combinations thereof.

6. The method in accordance with claim 1 , wherein the cysteine is chemically pure cysteine.

7. The method in accordance with claim 1 , wherein the cysteine treats an age related decrease in food intake.

8. The method in accordance with claim 1 , wherein the nutritional composition comprises the cysteine in an amount of at least 10 g/kg dry weight of the composition.

9. The method in accordance with claim 1 , wherein the nutritional composition is administered through a route selected from the group consisting of orally, enterally and parenterally, and wherein the nutritional composition is to be administered within one hour before a meal, during a meal, or as replacement of a meal.

10. A nutritional composition comprising at least 5 weight-% of chemically pure cysteine and from about 20 to 70% of the calories of the nutritional composition from carbohydrates.

11. The nutritional composition in accordance with claim 10 , wherein the nutritional composition has a caloric density of at least 0.5 kcal/g.

12. The nutritional composition in accordance with claim 10 , wherein the nutritional composition comprises about 10 to 40% of the calories of the nutritional composition from proteins.

13. The nutritional composition in accordance with claim 10 , wherein the nutritional composition comprises about 15 to 45% of the calories of the nutritional composition from lipids.

14. The nutritional composition in accordance with claim 10 , wherein the nutritional composition is selected from the group consisting of a food product, a pet food product, a drink, a pharmaceutical, a nutritional formula, a composition for clinical nutrition, a nutritional powder to be reconstituted by addition of water, a juice or milk, a nutraceutical, a food additive, a food supplement, a dairy product, and a gel.

15. A method for the prevention of malnutrition comprising the step of administering to an elderly subject a nutritional composition that contains from about 20 to 70% of the calories of the nutritional composition from carbohydrates and a protein fraction comprising at least 5 weight-% cysteine to increase food intake and/or decrease satiety and/or satiation.

16. The method in accordance with claim 15 , wherein the cysteine is provided in a form of a cysteine precursor selected from the group consisting of cysteine bound in a protein, a peptide hydrolysate, a peptide, and mixed disulfides.

17. The method in accordance with claim 15 , wherein the nutritional composition comprises the cysteine in an amount of at least 2 g/kg dry weight of the composition.

18. The method in accordance with claim 15 , wherein the cysteine increases appetite.

19. The method in accordance with claim 15 , wherein the cysteine is chemically pure cysteine.

20. The method in accordance with claim 15 , wherein the cysteine treats an age related decrease in food intake.

21. The method in accordance with claim 15 , wherein the nutritional composition comprises the cysteine in an amount of at least 10 g/kg dry weight of the composition.

22. The method in accordance with claim 1 , wherein the cysteine is provided in a form selected from the group consisting of gamma-glutamyl-cysteine, L-cysteine-glutathione cysteine prodrugs, N-acetyl-cysteine (free form, amide or ester forms), S-allyl-cysteine, S-methyl-cysteine, S-ethyl-cysteine, S-propyl-cysteine, TCA (thiazelidineScarboxylic acid), OTC (L-2-Oxothiazolidine-4-carboxylate), and S-hydroxy-methyl mercapto L-cysteine.

23. The method in accordance with claim 15 , wherein the cysteine is provided in a form selected from the group consisting of gamma-glutamyl-cysteine, L-cysteine-glutathione cysteine prodrugs, N-acetyl-cysteine (free form, amide or ester forms), S-allyl-cysteine, S-methyl-cysteine, S-ethyl-cysteine, S-propyl-cysteine, TCA (thiazelidineScarboxylic acid), OTC (L-2-Oxothiazolidine-4-carboxylate), and S-hydroxy-methyl mercapto L-cysteine.

24. The method in accordance with claim 1 , wherein the cysteine is administered in a daily dose of about 0.03 to 0.15 g/kg body weight.

25. The method in accordance with claim 15 , wherein the cysteine is administered in a daily dose of about 0.03 to 0.15 g/kg body weight.

26. The method in accordance with claim 1 , wherein the protein fraction comprises at least 10 weight-% cysteine.

27. The method in accordance with claim 15 , wherein the protein fraction comprises at least 10 weight-% cysteine.

Assignments (6)
CHANGE OF NAME Recorded Jan 12, 2021
From: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA)
To: INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT
Reel/Frame 054972/0888 →
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912. Recorded Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0001 →
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912. Recorded Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0165 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ENGLISH TRANSLATION TO SHOW THE FULL AND CORRECT NEW NAME IN SECTION 51. PREVIOUSLY RECORDED AT REEL: 049391 FRAME: 0756. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER. Recorded Jun 13, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049853/0398 →
MERGER Recorded Jun 6, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049391/0756 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2014
From: BREUILLE, DENIS; VIDAL, KARINE; PAPET, ISABELLE
To: NESTEC S.A.; INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA)
Reel/Frame 032118/0346 →